Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.99 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.25 | 3.87 | 2.77 | 4.69 | 5.38 | 6.26 | 6.10 | 9.51 | 6.05 | 9.04 | 7.61 | 6.51 | 7.55 |
| — | -38.1% | -54.5% | -50.7% | -11.2% | -30.8% | -19.8% | +45.9% | -19.8% | +28.8% | -3.2% | -18.5% | -35.3% | |
| P/B Ratio | — | — | — | 185.72 | 22.62 | 23.05 | 15.35 | 14.99 | 8.23 | 28.06 | 14.08 | 80.56 | 25.35 |
| — | — | — | +1138.8% | +174.8% | -17.8% | +9.0% | -81.4% | -67.5% | +119.2% | +52.8% | +1201.9% | +312.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ultragenyx Pharmaceutical Inc.'s operating margin was -124.3% in Q1 2026, down 69.2 pp QoQ and down 21.6 pp YoY. The trailing four-quarter average of -87.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 77.9% | 86.0% | 82.5% | 86.2% | 79.4% | 89.8% | 84.9% | 85.5% | 83.9% | 90.5% | 88.8% | 90.8% |
| — | -1.9% | -4.2% | -2.9% | +0.8% | -5.3% | -0.9% | -4.4% | -5.9% | -4.5% | -4.5% | -1.9% | +0.1% | |
| Operating Margin | -79.5% | -124.3% | -55.1% | -106.9% | -64.8% | -102.6% | -74.2% | -94.6% | -79.1% | -151.9% | -95.8% | -148.0% | -136.6% |
| — | -21.1% | +25.7% | -12.9% | +18.1% | +32.5% | +22.6% | +36.1% | +42.1% | +0.9% | +32.0% | +40.4% | +13.8% | |
| Net Margin | -85.4% | -136.0% | -62.3% | -112.8% | -69.0% | -108.5% | -80.9% | -95.7% | -89.5% | -156.8% | -96.7% | -162.8% | -147.6% |
| — | -25.4% | +23.0% | -17.9% | +22.9% | +30.8% | +16.3% | +41.2% | +39.3% | +3.9% | +34.2% | +39.7% | +16.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -607.5% | — | — | -206.8% | -74.3% | -73.1% | -43.3% | -34.0% | -46.0% | -82.1% | -80.2% | -198.6% | -91.5% |
| — | — | — | -509.0% | -61.6% | +11.0% | +46.0% | +82.9% | +49.7% | -43.5% | -117.0% | -364.7% | -326.3% | |
| ROA | -37.9% | -13.1% | -9.5% | -14.5% | -8.8% | -10.7% | -8.8% | -8.5% | -9.0% | -12.2% | -9.0% | -12.5% | -11.9% |
| — | -21.9% | -8.1% | -70.9% | +2.4% | +12.0% | +2.9% | +32.5% | +24.2% | -9.0% | +5.9% | +24.9% | -1.4% | |
| ROIC | -89.4% | -69.5% | -11.7% | -35.7% | -178.0% | -112.0% | -50.1% | -87.4% | -301.2% | -142.7% | -165.3% | -372.3% | -102.7% |
| — | +38.0% | +76.6% | +59.1% | +40.9% | +21.5% | +69.7% | +76.5% | -193.1% | -155.9% | -174.7% | -636.2% | -498.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 15.7% YoY to 2.02x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 54.76 | 0.23 | 0.25 | 0.15 | 0.10 | 0.09 | 0.29 | 0.16 | 1.47 | 0.20 |
| — | — | — | +56747.5% | +164.7% | -12.9% | -1.9% | -93.4% | -56.6% | +124.0% | +74.9% | +1887.1% | +260.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.48 | 2.02 | 2.48 | 1.89 | 2.45 | 2.40 | 2.37 | 2.81 | 3.54 | 2.43 | 2.61 | 2.36 | 2.87 |
| — | -15.7% | +4.3% | -32.6% | -30.6% | -1.2% | -9.1% | +18.9% | +23.0% | -30.9% | -22.8% | -47.0% | -6.6% | |
| Quick Ratio | 2.34 | 1.85 | 2.34 | 1.74 | 2.30 | 2.24 | 2.24 | 2.65 | 3.39 | 2.28 | 2.49 | 2.23 | 2.76 |
| — | -17.3% | +4.4% | -34.5% | -32.2% | -1.8% | -9.9% | +18.8% | +22.9% | -32.7% | -24.1% | -48.7% | -7.5% | |
| Interest Coverage | -8.63 | -8.05 | -6.00 | -11.69 | -7.12 | -9.44 | -7.59 | -7.48 | -7.19 | -9.74 | -6.32 | -8.00 | -9.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RARE stock.
Ultragenyx Pharmaceutical Inc.'s current P/E is -5.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ultragenyx Pharmaceutical Inc.'s current operating margin is -79.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ultragenyx Pharmaceutical Inc.'s business trajectory between earnings reports.